Surgeries & Interventions August 13, 2026
More Interventional Cardiologists, More Low-Value Stents August 13, 2026
The old adage that "built capacity gets used" applies to cardiology too. A Lown Institute study found that regions with the most PCI-performing physicians lead to a disproportionately higher share of patients receiving stents they’re unlikely to benefit from.
Cardiology Business August 10, 2026
iRhythm Expands MCT Footprint with VitalConnect Acquisition August 10, 2026
iRhythm, best known for its Zio cardiac monitoring wearables, is moving to expand well beyond its 14-day-patch roots by acquiring wearable biosensor company VitalConnect for $287.5M.
Cardiology Pharmaceuticals August 6, 2026
ZEUS Tells Us Inflammation Might Not Be the Answer August 6, 2026
Cardiovascular inflammation has been the talk of the town in cardiology, and while Novo Nordisk was wise to pursue treating it, results from the ZEUS trial have led to a thunderous debate on whether or not it ever played a role in ASCVD.
Cardiology August 3, 2026
How to Make Cardiologists Love Academia Again August 3, 2026
Cardiology is one of the most data-driven medical specialties a physician can pursue. So why is the source of that data – cardiac academia – declining in both workforce and prestige?
Cardiology Pharmaceuticals July 31, 2026
Another Look at Attruby Reveals Bolstered Benefits July 31, 2026
As the ATTR-CM market gets more crowded, medications will have to prove their place, and a sub-analysis of the ATTRibute-CM trial shows BridgeBio’s Attruby (acoramidis) has the efficacy to remain competitive.
Structural Heart July 30, 2026
Knowing When to Intervene in Mitral Regurgitation July 30, 2026
A common question in structural heart cardiology is “when do we know to intervene?” and recently released 25-year mitral regurgitation data might just have given us an answer.
Cardiology July 27, 2026
The Career Perceptions of Heart Failure Cardiology July 27, 2026
Picture this – you graduate medical school (not easy), you do a three-year internal medicine residency, then a three-year general cardiology fellowship, and another year of fellowship, but you’re paid less than your peers in other subspecialties – congrats, you’re an advanced heart failure cardiologist (AHFTC).
Cardiology Business July 23, 2026
The Cost of Cardiology is Driven by Insurers July 23, 2026
New price transparency data reveals how wildly insurance payments, reimbursements, and facility fees for cardiology swing across insurers and states, which underscores the complexity of U.S. healthcare costs.
Heart Failure July 22, 2026
How Earlier Hemodynamic Insight May Help Guide Heart Failure Management July 22, 2026
Heart failure continues to place a significant burden on patients and the healthcare system, with nearly 7 million Americans living with heart failure, with prevalence expected to reach nearly 9 million by 2030. Despite advances in guideline-directed medical therapy (GDMT), many patients still face high risks of hospitalization, mortality, and reduced quality of life.
Cardiology Pharmaceuticals July 20, 2026
An Oral PCSK9i and What it Means for Merck July 20, 2026
PCSK9 inhibitors are some of the most effective LDL-lowering drugs out there, but they’ve all required injection, and some even refrigeration. That just changed, however, with the FDA’s approval of Merck's Lipfendra (enlicitide), the first ever oral PCSK9i.
Cardiology Pharmaceuticals July 17, 2026
Can Kerendia Handle the (Blood) Pressure? More Findings from FINEARTS-HF. July 17, 2026
One year after its FDA approval for HF treatment, a new FINEARTS-HF substudy shows Bayer’s Kerendia (finerenone) isn’t just impervious to BP differences, it could actually give a small leg up to patients with hypertension.
Cardiac Imaging July 16, 2026
Zero CAC And The Cost of CCTA-QPA July 16, 2026
The power of a zero CAC score is facing fresh scrutiny after new plaque analysis data presented at SCCT 2026 shows just how much noncalcified plaque confers its own cardiovascular risk, despite the software’s financial barriers.
Heart Failure July 9, 2026
POLY-HF and the Possibility of HF Polypills July 9, 2026
Guideline-directed heart failure therapy works, but the biggest hurdle is getting patients to actually take it and fresh results in Nature from the POLY-HF trial suggest a polypill approach could be the answer.
Artificial Intelligence July 2, 2026
DETECT AS II and the Importance of Assertive Notifications July 2, 2026
We already know that passive EHR alerts improve severe aortic stenosis management, but the DETECT AS II study now suggests a more forceful “opt-out” approach could substantially increase how many patients get timely valve replacement.
Heart Failure July 2, 2026
Uncertainty Lingers on VNS for HF After Shortened Study July 2, 2026
Freshly published data from LivaNova’s pivotal ANTHEM-HFrEF trial hinted that vagal nerve stimulation might help patients with HFrEF, but the company's early termination decision left some questions unanswered.
Structural Heart June 29, 2026
EARLY TAVR 5-Year Data Answer Some Questions, Raise Others June 29, 2026
Whether or not to intervene early in asymptomatic aortic stenosis was answered by EARLY TAVR in 2024, and new 5-year data presented at NYV 2026 now suggests that the benefit of early intervention is driven by reductions in death and stroke rather than just heart failure.
Cardiology Practices June 25, 2026
APPs are Growing in Compensation and Relevance in Cardiology June 25, 2026
Advanced practice providers have long been viewed as support staff in cardiology, but MedAxiom's new 2025 APP Compensation and Utilization Report suggests they've moved well beyond that role.
Heart Failure June 22, 2026
Heart Failure GDMT Reduces Hospitalizations and Financial Burden June 22, 2026
The four-drug guidelines for heart failure with reduced ejection fraction are well established to cut hospitalizations and a new economic analysis in JAMA suggests that the hospital cost-savings more than cover the cost of the drugs themselves.
Surgeries & Interventions June 18, 2026
Ten Year TAVR Data and Why Valve Generations Matter June 18, 2026
TAVR has been among the default therapies for aortic stenosis patients for years now, but new 10-year data from the PARTNER 2A trial and the P2S3i Sapien 3 registry suggests that how long a valve will last depends heavily on the valve’s generation.